Evaluation of a point of care lateral flow assay for antibody detection following SARS CoV-2 mRNA vaccine series.

ABSTRACT:

Background

Breakthrough cases of SARS-CoV-2 infection correlate with decreased antibody immunity following mRNA vaccination. Measuring kinetics of vaccine efficacy using traditional laboratory approaches is more expensive and can be impractical. In this study, we evaluated the diagnostic performance of a validated COVID-19 point-of-care lateral flow assay (LFA) kit in detecting post-vaccination antibody response.

Methods

We conducted a prospective cohort study of whole blood and plasma samples to evaluate the performance of a LFA in detecting SARS-CoV-2-specific antibodies following mRNA vaccination compared to enzyme-linked immunosorbent assays (ELISAs). Health care workers at 2 tertiary centers who completed an initial BNT162b2 (n = 103) or mRNA-1273 (n = 35) vaccine serie

SUBMITTER: Lee W 

PROVIDER: S-EPMC9797226 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature